Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Orchestra BioMed Holdings, Inc. (OBIO)

Orchestra BioMed posts September 2026 investor presentation with pipeline and trial timelines

Neutral Impact 1 of 5 other Written later

Orchestra BioMed filed a slide presentation used at investor and industry conferences as Exhibit 99.1 to an 8-K furnished under Regulation FD. The deck covers its AVIM Therapy and Virtue SAB programs, partner funding of more than $185 million, and cash runway through 2027, with no new financial results reported in the filing.

Key points

  • Partners Medtronic, Terumo and Ligand have provided more than $185 million of strategic capital, per the presentation.
  • BACKBEAT pivotal trial primary endpoint data targeted for Q2 2027; target enrollment completion in Q3 2026.
  • Virtue Pivotal Trial is actively enrolling 740 patients; the presentation says current cash provides runway through 2027.

The filing

CompanyOrchestra BioMed Holdings, Inc. (OBIO)
Form8-K, current report
Filed with the SECSep 8, 2026, 9:30 AM ET
Accession number0001104659-26-105733

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 08, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.